AbbVie's Etentamig meets Phase III Trial endpoints in patients with triple-class exposed relapsed/refractory multiple myeloma
AbbVie announced that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).
Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings.
Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma.
The full list of AbbVie presentations at IMS includes:
|
Abstract Title |
Date/Time |
Session |
Abstract Number |
|
Real-World (RW)Characteristics, Treatment Patterns, and Outcomes (TCE) (RRMM) in Europe: Data Platform
|
Wednesday,
12:00–1:00 PM |
Poster Presentation
|
PA-386 |
|
Etentamig in Patients with Multiple Myeloma (RRMM)
|
Thursday, September
12:00–1:00 PM |
Poster Presentation
|
PA-181 |
|
A Phase 1/2, Open-Label, Evaluate the Safety and Monotherapy or
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation
|
PA-008 |
|
Phase 1/2, Open-Label, Selected Patients with Multiple Myeloma (RRMM)
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation |
PA-346 |
|
Real-World (RW) T-cell Redirecting
|
Friday, September 25,
12:00–1:00 PM |
Poster Presentation
|
PA-387 |
|
CERVINO: Phase (Ph) 3 Investigator's Choice of Therapies (SAT) in Exposed Relapsed or (RRMM)
|
Friday, September 25,
3:00–5:00 PM |
Plenary Session
Hall 5 |
LBA-01 |
|
Etentamig Combined With Dexamethasone Refractory Multiple Prior Lines of Therapy: A
|
Saturday, September
8:30–9:30 AM
|
Oral Presentation
Abstract Session 9
Hall 5 |
OA-24 |
|
AbbVie Advances ABBV-
|
Saturday, September
9:30–10:20 AM |
Oral Presentation
Future Targets and
Hall 5
|
N/A |
|
Surzetoclax: A Potentially Inhibitor for the Treatment with t(11;14) Translocation Expression
|
N/A |
Poster Presentation
|
PA-468 |
Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
Source: Press Release